

REVIEW **OPEN**


PATET ratio by Doppler echocardiography: noninvasive detection of pediatric pulmonary arterial hypertension

Jennifer K. Trittman^{1,2}✉, Hanadi Almazroue¹, Leif D. Nelin^{1,2}, Terri A. Shaffer³, Charanda R. Celestine⁴, Henry W. Green3rd⁴ and Raphael A. Malbrue^{3,5}

© The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc 2021

Pulmonary artery acceleration time (PAT) and PAT: ejection time (PATET) ratio are echocardiographic measurements of pulmonary arterial hypertension (PAH). These noninvasive quantitative measurements are ideal to follow longitudinally through the clinical course of PAH, especially as it relates to the need for and/or response to treatment. This review article focuses on the current literature of PATET measurement for infants and children as it relates to the shortening of the PATET ratio in PAH. At the same time, further development of PATET as an outcome measure for PAH in preclinical models, particularly mice, such that the field can move forward to human clinical studies that are both safe and effective. Here, we present what is known about PATET in infants and children and discuss what is known in preclinical models with particular emphasis on neonatal mouse models. In both animal models and human disease, PATET allows for longitudinal measurements in the same individual, leading to more precise determinations of disease/model progression and/or response to therapy.

Pediatric Research (2022) 92:631–636; <https://doi.org/10.1038/s41390-021-01840-9>

IMPACT:

- PATET ratio is a quantitative measurement by a noninvasive technique, Doppler echocardiography, providing clinicians a more precise/accurate, safe, and longitudinal assessment of pediatric PAH.
- We present a brief history/state of the art of PATET ratio to predict PAH in adults, children, infants, and fetuses, as well as in small animal models of PAH.
- In a preliminary study, PATET shortened by 18% during acute hypoxic exposure compared to pre-hypoxia.
- Studies are needed to establish PATET, especially in mouse models of disease, such as bronchopulmonary, as a routine measure of PAH.

INTRODUCTION

Pulmonary arterial hypertension (PAH) is a disease characterized by right heart catheter measurement of mean pulmonary arterial pressure (mPAP) >20 mm Hg at rest, according to the recent 6th World Symposium.¹ Over time PAH can lead to right ventricular failure and death in any age group. In infants and children, PAH can occur as a result of the chronic lung disease of prematurity, bronchopulmonary dysplasia (BPD). The World Health Organization (WHO) PH classification system places PAH associated with BPD into group 3,² wherein the pulmonary vasculature is relatively contracted and/or remodeled, decreasing vessel diameter. Monitoring for PAH in high-risk populations such as BPD patients is crucial for early PAH diagnosis and management. Catheter-based hemodynamic measurements are invasive, usually requiring anesthesia, and therefore not ideal in many clinical situations, such as a patient who is small (neonatal/infant), has poor vascular integrity, and/or requires long-term right ventricular pressure (RVP) monitoring. Alternatively, RVP monitoring by pulsed-wave Doppler echocardiography using pulmonary artery acceleration time (PAT): ejection time (PATET) ratio is noninvasive, quantitative,

and more easily assessed than tricuspid regurgitation measurement³ with high intra- and interobserver agreement.⁴ Since early diagnosis and treatment of PAH are vitally important to slow PAH development and prevent PAH-associated morbidity and mortality, PATET has evolved as a useful clinical predictor of PAH in many clinical settings in adults. However, its use is relatively new in small children, particularly infants. Therefore, the aims of this review are to (1) examine the use of PATET as a quantitative clinical tool to assess PAH in the current pediatric literature and (2) discuss the utility of PATET measurement in small animal models of PAH.

PAT AND PATET RATIO

PAT, also known as PAAT, PA_cT, or time to peak velocity, is the time (in ms) it takes for blood from the right ventricle to exit through the pulmonary valve and reach peak velocity after the pulmonary valve opens during systole. PAT is inversely related to heart rate (HR),^{5–7} and adjustment for HR is made by dividing by the right ventricular ET ((RV)ET) to get the PATET.⁸ When PAP is elevated, as in the case of PAH, tachycardia has less of an effect on

¹Center for Perinatal Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA. ²Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, OH, USA. ³Animal Resources Core, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA. ⁴Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA, USA. ⁵College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA. ✉email: jennifer.trittmann@nationwidechildrens.org

Received: 26 May 2021 Revised: 9 October 2021 Accepted: 28 October 2021
 Published online: 18 November 2021

the PAT.⁹ The (RV)ET is the total time (in ms) it takes for blood from the right ventricle to exit through the pulmonary valve during one systolic cycle, from the opening to the closing of the pulmonary valve.¹⁰ The PATET then is the ratio of these two time intervals, which gives a unitless (ms/ms) proportion, whereby the smaller the proportion (shortening of the PATET), the less time per cycle is spent getting to peak velocity, indicative of higher mPAP. Stated another way, when mPAP is elevated, as measured by elevated right ventricular systolic pressure (RVSP), it will take a shorter time for blood flow from the pulmonary artery to reach maximum velocity (faster flow acceleration),^{11,12} and the PATET ratio will be decreased/shortened. In summary, the shorter the PATET, the worse the PAH, reflecting the indirect relationship of PATET and measures of PAH including RVSP, PAP, and pulmonary vascular resistance (PVR), as well as the direct relationship of PATET and measures of PAH including pulmonary arterial compliance and RV mechanical performance.^{3,5,7}

ADULT PAT

PAT research was first conducted in adults who normally have baseline HR < 100 b.p.m. The correction for HR with ET was, therefore, less of a concern and had not yet been introduced in the literature. The following studies are in adults and evaluated by transthoracic echocardiography unless otherwise noted. In 1983, Kitabatake et al. were the first to discover that PAT shortened as mPAP increased (mean PAT = 137 ms when mPAP < 20 mm Hg, mean PAT = 97 ms when mPAP > 20 mm Hg).¹² Also, in the 1980s, the linear, inverse relationship between PAT and mPAP was established, within a PAT range of 74–170 ms.^{5,12–15} Currently, PAT is used either independently or in conjunction with tricuspid regurgitation velocity (TRV) to predict PAH,^{6,7,14,16,17} and PAT and TRVmax are inversely correlated.¹⁸ Granstam et al. confirmed that PAT is a clinically useful tool, especially in high-risk patients, and reported that a PAT < 100 ms is strongly associated with PAH.¹⁹ In 2015, Tousignant and Van Orman studied patients undergoing elective cardiac surgery, where simultaneous hemodynamic measurements by trans-esophageal echocardiography and catheter-based pulmonary capillary wedge pressure showed that PAT correlated with invasive hemodynamic parameters.²⁰ In 2016, Cowie et al. also studied cardiac surgical patients and found that PAT < 107 ms predicted PAH.²¹ More recently, Zhan et al. utilized PAT to classify PAH severity (mild 70–90 ms, medium 50–70 ms, and severe < 50 ms).²² Interestingly, adults exposed to hyperoxia (100% O₂) had modestly lengthened PAT, whereas hypoxia (17% O₂) had minimal effect.²³ PAT can also be used to predict cardiovascular events in young adults.²⁴

CHILDREN PAT AND PATET

For children, the use of PAT to predict PAH can vary by age, body surface area, and HR. There is a positive correlation of PAT and age, PAT and body surface area, and a negative correlation of PAT and HR.⁷ Overall in children, detection of elevated PVR, decreased pulmonary arterial compliance, and RV dysfunction occurs at PAT < 90 ms and PATET < 0.3,^{3,10} and PATET < 0.29 predicts PAH with 100% sensitivity and 96% specificity.^{6,7} In 1984, Kosturakis et al. reported a range of PAT in children of 51–140 ms.²⁵ In a cohort of both children and adults with cystic fibrosis, PAT < 101 ms was proposed as a useful decision-making tool for clinicians regarding the timing of lung transplantation.²⁶

INFANT PAT AND PATET

PATET and TRV are the major quantitative echocardiographic measurements in older children and adults to predict PAH. As patients become smaller, the TRV is more difficult to assess, thus

the importance of measuring PAT and PATET. In both infants and children, PAT has been shown to predict PAP, PVR, and vascular compliance as measured by cardiac catheterization.^{3,6,10} In 2008, at a time when PATET was not yet routinely measured, Mourani et al. stated that the accurate estimate of catheter-based systolic PAP by echocardiographic quantitative measurements was much needed, especially in children < 2 years of age.²⁷ In 2020, PAT was found to correlate with systolic PAP as estimated by TRV in neonates and young infants using the equation: sPAP = 82.6 – 0.58 × PAT + right atrial (RA) mean pressure.²⁸

PRETERM INFANT PAT AND PATET

A study by Carlton et al. in 2017 found that quantitative (PATET and TRV) echocardiographic measurements of PAH were more reliable among cardiologists than qualitative measurements in the assessment of pulmonary vascular disease in preterm neonates.²⁹ Indeed, much of the PATET literature in infants has focused on preterm infants, with and without comorbidities such as bronchopulmonary dysplasia.

In healthy preterm infants, PATET increases longitudinally from birth to 1 year of age, indicative of the normal decrease in RV afterload that occurs postnatally.⁴ In the 1990s, Gill and Weindling studied the natural history of PATET in a cohort of very low birthweight infants and found that the PATET becomes greater over the first 3 weeks of life, corresponding to the normal drop in PVR. In addition, those patients who continued to require supplemental oxygen after 36 weeks postmenstrual age had a lower PATET than room air controls,^{30,31} and PATET could be used to predict preterm patients that would develop chronic lung disease.^{32,33} Levy et al. published PATET values for a cohort of preterm patients at 1 year of age and found that PATET was lower in patients with PAH than in those without PAH.^{3,5} In patients ≤ 1 year of age, some of which were preterm with BPD and/or patent ductus arteriosus (PDA), infant PAT was inversely related to mPAP, systolic PAP, and PVR.⁵ Interestingly, when BPD-PH patients received either 100% O₂ or 20 p.p.m. nitric oxide, PATET lengthened, indicative of improved PAP.³⁴

PRENATAL PAT AND PATET

In 1987, Machado et al. reported the first human fetal (16–30 weeks gestation) PAT, as well as aortic AT, and found that PAT was shorter than aortic AT, consistent with the fetal circulatory pattern.³⁵ In 2003, Fuke et al. predicted pulmonary hypoplasia using shorter fetal PATET obtained antenatally (20–39 weeks gestation). Normal values for mean PATET were also obtained in both right (0.17) and left (0.15) fetal pulmonary arteries.³⁶ Additional antenatal human fetal studies have shown that mean PAT and PATET lengthen with increasing gestational age (18 weeks: PAT = 24 ms, PATET = 0.14; 38 weeks: PAT = 36 ms, PATET = 0.20), likely reflecting normal fetal pulmonary vascular development, decreasing PVR, and increasing pulmonary blood flow.^{37–39}

PAT AND PATET IN SMALL ANIMALS

PAH has been studied in canines, which, like humans, can develop PAH in response to underlying respiratory disease and left-sided heart disease. In addition, canine PAH is commonly associated with degenerative valve disease and parasites, such as heartworms. Veterinarians routinely use echocardiography clinically to diagnose and assess PAH; however, this can be challenging given the diverse number of species, and factors such as size, breed, and anatomical complexities.⁴⁰ The American College of Veterinary Internal Medicine recently published a consensus statement providing a guideline for the diagnosis, classifying, treating, and

monitoring of canine PAH.⁴⁰ One of the recommendations includes evaluating anatomical sites, such as the pulmonary artery using echocardiography. RV outflow doppler time (similar to PAT) < 52–58 ms or PATET < 0.30 has been shown to suggest a higher probability of PAH in canines.^{40–43} In addition, systolic notching of the Doppler RV outflow profile can assist in determining PAH in veterinary species.⁴⁰

Early studies in mice had difficulty visualizing the heart by echocardiography because of high heart rate (>400 b.p.m.) and small size.^{44,45} However, recent advances in technology, as well as comprehensive protocols to assess the right heart in mice, have overcome these barriers with great potential to advance the study of PAH in mouse models.^{46–48} Echocardiographic probes are now miniaturized with frequencies >30 MHz designed for rodents.^{49–51} Echocardiographic landmarks in mice that are relevant to PAH include right ventricle, right ventricular outflow tract (PAT measurement), and tricuspid valve (TRV measurement).⁵² PAT and TRV can then be used to calculate PVR.^{53–55}

In a seminal article by Thibault et al. in 2010, mice underwent echocardiography and PATET was compared to pressures obtained from right ventricle catheterization at 3 months of age, which are currently the youngest mice studied using catheterization and echocardiography. It was determined that PATET < 0.39 detected elevated RVSP (>32 mm Hg) with sensitivity of 100% and specificity of 86%, while keeping both intra- and interobserver variability at <6%.⁵⁶ This demonstrated that PATET by echocardiography could be used to accurately assess PAH in mice >3 months of age. However, the question still remains as to whether PATET by echocardiography can be utilized to assess PAH in mice <3 months of age.

Recently, PAT and PATET have been routinely measured in several PAH mouse models, adult and neonatal. Although the great strength of mouse models is the ability to interrogate genetic molecular targets causal to the disease phenotype of interest, many of the PAH mouse models are environmental exposures. A study in adult mice exposed to 3 weeks of hypoxia and repeated exposure to SU5416 (VEGF receptor inhibition) showed shortening of the PATET, as well as increases in RV wall thickness measured in diastole, compared to control.⁴⁴ In a study by Zhu et al. 2019, an 8-week hypoxic mouse model and two rat models (hypoxia/sugen and MCT) showed shortening of the PATET compared to control.⁵⁷ Adiponectin knockout mice have shortening of the PATET and evidence of PAH at 1 year of age.⁵⁸ PATET has also been used to longitudinally evaluate adult mice with a congenital diaphragmatic hernia for PAH.⁵⁹ Reynolds et al. in 2016, evaluated newborn C57BL/6J mice in 70% O₂ at 14 days and found evidence of shortening of the PATET, demonstrating PAH in the youngest cohort of mice to be reported at this time.⁶⁰

EXPERIMENT: PAT AND PATET IN A PAH HYPOXIC MOUSE MODEL

We recently evaluated PATET by echocardiography⁵⁵ in anesthetized 28-day-old C57BL mice before, during an acute hypoxic exposure-induced PAH, and recovery in hyperoxia (50% O₂) (Fig. 1). We measured appreciable shortening (by 18%) of the PATET during acute hypoxic exposure (mean PATET = 0.211) compared to pre-hypoxia (mean PATET = 0.257), and recovery of PATET with hyperoxia at 1 min, $p = 0.014$). These data confirm that PATET can be reliably repeatedly measured in 28-day-old mice and that shortening of the PATET, consistent with elevated PAP, can be observed in acute exposure to hypoxia. These data confirm previous studies^{56,60} that PAT and PATET measurements are important tools to assess PAH even in very young mice. A mouse model such as this will be very useful in studying the progression of PAH disease, particularly in the context of models of human disease such as persistent pulmonary hypertension of the newborn or BPD.




Fig. 1 PATET shortening in PAH hypoxic mouse model. Echocardiography with PATET measurement in 28-day-old C57BL mice before (pre-21% O₂), during hypoxia (10% O₂), and recovery with hyperoxia (50% O₂). Mice were anesthetized with inhaled 1–3% isoflurane during the experiment. Each mouse ($N = 9$) had 3–10 data points that were averaged prior to the calculation of mean ± SE presented. Repeated-measures one-way ANOVA with Tukey's multiple comparisons test. *10% O₂ vs. 50% O₂—1 min, $p = 0.014$; 10% O₂ vs. 50% O₂—3 min, $p < 0.001$; 10% O₂ vs. 50% O₂—10 min, $p < 0.01$.

PAT AND PATET LIMITATIONS

There are general limitations of small animal models, including the areas of studying breathing mechanics, gas exchange, and pulmonary hemodynamics,⁶¹ especially catheterization. Because of the difficulty to catheterize extremely small neonatal mice, we focus on developing PATET by echo as a potential solution. However, there are several limitations and/or considerations that need to be addressed when analyzing PAT and PATET data. The operator technique is important in acquiring data from Doppler echocardiography, including operator variation in determining the optimal angle between the transducer and pulmonary artery.⁶² This is an issue especially with smaller individuals, and it has been shown that the measurement of blood velocity decreases as the misalignment in the angle increases, and at >20% difference clinically the test is no longer considered accurate.^{46,63} Another consideration is that PAT measurements when expressed as a range are not continuous because the Doppler waveform is derived from intermittent Fourier analysis.²³ Some researchers have proposed magnetic resonance imaging (MRI) as a better modality to estimate PATET,⁶² and at least three studies in patients with bronchopulmonary dysplasia have determined that another quantitative measurement, eccentricity index, may be a better measure of right ventricular mechanics.^{64–66} Guidelines for measuring cardiopulmonary physiology by both echocardiography and MRI have been published and are an important step forward in the development of preclinical animal models.^{67,68} Despite superior imaging of MRI and micro-computed tomography,⁶⁹ the primary advantage of echo assessment is that the echo probe technique and PATET measurement can be (1) studied on a mouse prior to clinical use on a neonatal patient and (2) measured in real-time (functional echocardiography⁷⁰) with relatively little anesthesia. Anesthesia can have negative impacts include hypercarbia, acidosis, hypothermia, alteration to ventilation/perfusion matching, tidal volume, and hypoxia resulting in pulmonary vasoconstriction.^{71–73} Any of these changes could alter the PAT and PATET ratio, but have so far not been studied. In addition, exploration of alternative anesthetic protocols to achieve a reduction in minimum alveolar concentration for volatile agents and their negative impacts is needed.

It is important to note that PAP estimation by maximal TRV in the absence of pulmonary stenosis continues to be the gold standard

echocardiographic measurement to estimate systolic PAP.^{5,11,74–76} However, the TR envelope is not accessible much of the time,^{5,77,78} whereas PATET is accessible in >90% of patients.^{11,68} In mice, TR occurs only in severe PH, and because of problems with flow alignment, measurements by echo are prone to inaccuracy.^{45,60} In addition, studies in both children and adults have put the TRV under scrutiny, with some published data that TRV does not accurately predict right heart catheterization measurements.^{10,79}

In preterm neonates, PATET may not be useful in the context of PDA with left-to-right shunting. PDA causes turbulent flow in the pulmonary artery, potentially altering PATET measurement.^{5,6,10,80} Gaulton et al. studied 57 infants (77% with PDA) who had both an echocardiogram and catheterization done within 10 days of each other and found that there was a correlation between PAT and PAP at catheterization, but no correlation between PATET and PAP at catheterization,⁷ highlighting the ambiguity of data interpretation in the context of PDA.

Discussion on the correction for HR made in the calculation of PATET was presented earlier under the heading “PAT and PATET ratio.” However, further adjustments have been proposed by correcting for the RR interval. Tossavainen et al. in 2013 corrected for HR by calculating a corrected PAT using the formula PAT/\sqrt{RR} interval, finding in adults that a corrected PAT < 90 ms is a good predictor of PVR > 3 Wood units.¹⁷ Interestingly, in neonatal patients, studies have not shown a correlation between PAT or PATET and RR interval.^{10,80,81}

Besides HR and large left-to-right shunts, RV dysfunction due to reasons other than PAH can also confound the PATET, such that the PATET should routinely be interpreted in the context of measurements of RV systolic function and shunts.⁸⁰ There are also considerations specific to the fetus including early RV and LV developmental effects on intrinsic contractile properties, vascular impedance, the capacitance of the vascular bed, and ventricular preload, which should be taken into consideration while interpreting the fetal PATET.⁸²

CONCLUSIONS

PAT and PATET are useful tools for the study of PAH in neonates, infants, and children, although further studies are needed to determine optimal cut-off values that have a robust correlation with PAH as diagnosed by catheterization. Furthermore, studies are needed to differentiate normal developmental changes from changes that are attributable to disease progression. In terms of preclinical studies, the mouse model is of particular interest given its widespread use for studying neonatal diseases and developmental changes. Further study to establish PATET as a routine and accurate measure of PAH in small and large animal models is needed to provide a noninvasive, longitudinal measure of PAH. For preclinical studies in neonatal mice to study PAH in bronchopulmonary dysplasia, early time points (day of life 14–28), when catheterization may be limited, validation of PATET against Fulton's index and/or pulmonary vascular histology may be necessary. Consideration of neonatal functional echo studies⁷⁰ that include PATET as a real-time tool for a bedside PAH evaluation that is reliable and accurate would greatly advance assessment and treatment plans for these very sick infants.

REFERENCES

- Simonneau, G. et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur. Respir. J.* **53**, 1–13 (2019).
- Nef, H. M., Mollmann, H., Hamm, C., Grimminger, F. & Ghofrani, H. A. Pulmonary hypertension: updated classification and management of pulmonary hypertension. *Heart* **96**, 552–559 (2010).
- Levy, P. T., Patel, M. D., Choudhry, S., Hamvas, A. & Singh, G. K. Evidence of echocardiographic markers of pulmonary vascular disease in asymptomatic infants born preterm at one year of age. *J. Pediatr.* **197**, 48–56.e42 (2018).
- Patel, M. D. et al. Echocardiographic assessment of right ventricular afterload in preterm infants: maturational patterns of pulmonary artery acceleration time over the first year of age and implications for pulmonary hypertension. *J. Am. Soc. Echocardiogr.* **32**, 884–894.e884 (2019).
- Gaulton, J. S. et al. Relationship between pulmonary artery acceleration time and pulmonary artery pressures in infants. *Echocardiography* **36**, 1524–1531 (2019).
- Koestenberger, M. et al. Normal reference values and z scores of the pulmonary artery acceleration time in children and its importance for the assessment of pulmonary hypertension. *Circ. Cardiovasc. Imaging* **10**, 1–12 (2017).
- Habash, S. et al. Normal values of the pulmonary artery acceleration time (Paat) and the right ventricular ejection time (Rvet) in children and adolescents and the impact of the Paat/Rvet-index in the assessment of pulmonary hypertension. *Int. J. Cardiovasc. Imaging* **35**, 295–306 (2019).
- Gardin, J. M. et al. Effect of acute changes in heart rate on doppler pulmonary artery acceleration time in a Porcine Model. *Chest* **94**, 994–997 (1988).
- Mallery, J. A., Gardin, J. M., King, S. W., Ey, S. & Henry, W. L. Effects of heart rate and pulmonary artery pressure on doppler pulmonary artery acceleration time in experimental acute pulmonary hypertension. *Chest* **100**, 470–473 (1991).
- Levy, P. T. et al. Pulmonary artery acceleration time provides a reliable estimate of invasive pulmonary hemodynamics in children. *J. Am. Soc. Echocardiogr.* **29**, 1056–1065 (2016).
- Wang, Y. C., Huang, C. H. & Tu, Y. K. Pulmonary hypertension and pulmonary artery acceleration time: a systematic review and meta-analysis. *J. Am. Soc. Echocardiogr.* **31**, 201–210 e203 (2018).
- Kitabatake, A. et al. Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique. *Circulation* **68**, 302–309 (1983).
- Dabestani, A. et al. Evaluation of pulmonary artery pressure and resistance by pulsed doppler echocardiography. *Am. J. Cardiol.* **59**, 662–668 (1987).
- Chan, K. L. et al. Comparison of three Doppler ultrasound methods in the prediction of pulmonary artery pressure. *J. Am. Coll. Cardiol.* **9**, 549–554 (1987).
- Matsuda, M. et al. Reliability of non-invasive estimates of pulmonary hypertension by pulsed Doppler echocardiography. *Br. Heart J.* **56**, 158–164 (1986).
- Marra, A. M. et al. Reference ranges and determinants of right ventricle outflow tract acceleration time in healthy adults by two-dimensional echocardiography. *Int. J. Cardiovasc. Imaging* **33**, 219–226 (2017).
- Tossavainen, E. et al. Pulmonary artery acceleration time in identifying pulmonary hypertension patients with raised pulmonary vascular resistance. *Eur. Heart J. Cardiovasc. Imaging* **14**, 890–897 (2013).
- Yared, K. et al. Pulmonary artery acceleration time provides an accurate estimate of systolic pulmonary arterial pressure during transthoracic echocardiography. *J. Am. Soc. Echocardiogr.* **24**, 687–692 (2011).
- Granstam, S. O., Bjorklund, E., Wikstrom, G. & Roos, M. W. Use of echocardiographic pulmonary acceleration time and estimated vascular resistance for the evaluation of possible pulmonary hypertension. *Cardiovasc. Ultrasound* **11**, 7 (2013).
- Tousignant, C. & Van Orman, J. R. Pulmonary artery acceleration time in cardiac surgical patients. *J. Cardiothorac. Vasc. Anesth.* **29**, 1517–1523 (2015).
- Cowie, B., Kluger, R., Rex, S. & Missant, C. The relationship between pulmonary artery acceleration time and mean pulmonary artery pressure in patients undergoing cardiac surgery: an observational study. *Eur. J. Anaesthesiol.* **33**, 28–33 (2016).
- Zhan, H. Y., Xu, F. Q., Liu, C. X. & Zhao, G. Clinical applicability of monitoring pulmonary artery blood flow acceleration time variations in monitoring fetal pulmonary artery pressure. *Adv. Clin. Exp. Med.* **27**, 1723–1727 (2018).
- Ernst, J. H. & Goldberg, S. J. Do changes in fraction of inspired oxygen affect pulmonary artery acceleration time? *Am. J. Cardiol.* **65**, 252–254 (1990).
- Moreira, H. T. et al. Pulmonary artery acceleration time in young adulthood and cardiovascular outcomes later in life: the coronary artery risk development in young adults study. *J. Am. Soc. Echocardiogr.* **33**, 82–89.e81 (2020).
- Kosturakis, D., Goldberg, S. J., Allen, H. D. & Loeber, C. Doppler echocardiographic prediction of pulmonary arterial hypertension in congenital heart disease. *Am. J. Cardiol.* **53**, 1110–1115 (1984).
- Damy, T. et al. Pulmonary acceleration time to optimize the timing of lung transplant in cystic fibrosis. *Pulm. Circ.* **2**, 75–83 (2012).
- Mourani, P. M., Sontag, M. K., Younoszai, A., Ivy, D. D. & Abman, S. H. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. *Pediatrics* **121**, 317–325 (2008).
- Mohammad Nijres, B. et al. Utility of pulmonary artery acceleration time to estimate systolic pulmonary artery pressure in neonates and young infants. *Pediatr. Cardiol.* **41**, 265–271 (2020).
- Carlton, E. F. et al. Reliability of echocardiographic indicators of pulmonary vascular disease in preterm infants at risk for bronchopulmonary dysplasia. *J. Pediatr.* **186**, 29–33 (2017).

30. Gill, A. B. & Weindling, A. M. Raised pulmonary artery pressure in very low birthweight infants requiring supplemental oxygen at 36 weeks after conception. *Arch. Dis. Child Fetal Neonatal Ed.* **72**, F20–F22 (1995).
31. Gill, A. B. & Weindling, A. M. Pulmonary artery pressure changes in the very low birthweight infant developing chronic lung disease. *Arch. Dis. Child* **68**, 303–307 (1993).
32. Subhedar, N. V., Hamdan, A. H., Ryan, S. W. & Shaw, N. J. Pulmonary artery pressure: early predictor of chronic lung disease in preterm infants. *Arch. Dis. Child Fetal Neonatal Ed.* **78**, F20–F24 (1998).
33. Su, B. H., Watanabe, T., Shimizu, M. & Yanagisawa, M. Doppler assessment of pulmonary artery pressure in neonates at risk of chronic lung disease. *Arch. Dis. Child Fetal Neonatal Ed.* **77**, F23–F27 (1997).
34. Sehgal, A., Blank, D., Roberts, C. T., Menahem, S. & Hooper, S. B. Assessing pulmonary circulation in severe bronchopulmonary dysplasia using functional echocardiography. *Physiol. Rep.* **9**, e14690 (2021).
35. Machado, M. V., Chita, S. C. & Allan, L. D. Acceleration time in the aorta and pulmonary artery measured by doppler echocardiography in the midtrimester normal human fetus. *Br. Heart J.* **58**, 15–18 (1987).
36. Fuke, S. et al. Antenatal prediction of pulmonary hypoplasia by acceleration time/ejection time ratio of fetal pulmonary arteries by Doppler blood flow velocimetry. *Am. J. Obstet. Gynecol.* **188**, 228–233 (2003).
37. Chaoui, R. et al. Doppler echocardiography of the main stems of the pulmonary arteries in the normal human fetus. *Ultrasound Obstet. Gynecol.* **11**, 173–179 (1998).
38. Rasanen, J., Huhta, J. C., Weiner, S., Wood, D. C. & Ludomirski, A. Fetal Branch pulmonary arterial vascular impedance during the second half of pregnancy. *Am. J. Obstet. Gynecol.* **174**, 1441–1449 (1996).
39. Azpuru, H. et al. Acceleration/ejection time ratio in the fetal pulmonary artery predicts fetal lung maturity. *Am. J. Obstet. Gynecol.* **203**, 40 e41–40.e48 (2010).
40. Reiner, C. et al. Acvim Consensus Statement Guidelines for the Diagnosis, Classification, Treatment, and Monitoring of Pulmonary Hypertension in Dogs. *J. Vet. Intern Med* **34**, 549–573 (2020).
41. Visser, L. C., Im, M. K., Johnson, L. R. & Stern, J. A. Diagnostic value of right pulmonary artery distensibility index in dogs with pulmonary hypertension: comparison with doppler echocardiographic estimates of pulmonary arterial pressure. *J. Vet. Intern. Med.* **30**, 543–552 (2016).
42. Serres, F. et al. Diagnostic value of echo-Doppler and tissue doppler imaging in dogs with pulmonary arterial hypertension. *J. Vet. Intern. Med.* **21**, 1280–1289 (2007).
43. Schober, K. E. & Baade, H. Doppler echocardiographic prediction of pulmonary hypertension in west highland white terriers with chronic pulmonary disease. *J. Vet. Intern. Med.* **20**, 912–920 (2006).
44. Ciucan, L. et al. A novel murine model of severe pulmonary arterial hypertension. *Am. J. Respir. Crit. Care Med.* **184**, 1171–1182 (2011).
45. Jones, J. E. et al. Serial noninvasive assessment of progressive pulmonary hypertension in a rat model. *Am. J. Physiol. Heart Circ. Physiol.* **283**, H364–H371 (2002).
46. Brittain, E., Penner, N. L., West, J. & Hemnes, A. Echocardiographic assessment of the right heart in mice. *J. Vis. Exp.* 1–8 (2013).
47. Kohut, A., Patel, N. & Singh, H. Comprehensive echocardiographic assessment of the right ventricle in murine models. *J. Cardiovasc. Ultrasound* **24**, 229–238 (2016).
48. Mocerri, P. et al. Imaging in pulmonary hypertension: focus on the role of echocardiography. *Arch. Cardiovasc. Dis.* **107**, 261–271 (2014).
49. Urboniene, D., Haber, I., Fang, Y. H., Thenappan, T. & Archer, S. L. Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension. *Am. J. Physiol. Lung Cell Mol. Physiol.* **299**, L401–L412 (2010).
50. Badea, C. T., Bucholz, E., Hedlund, L. W., Rockman, H. A. & Johnson, G. A. Imaging methods for morphological and functional phenotyping of the rodent heart. *Toxicol. Pathol.* **34**, 111–117 (2006).
51. Rey-Parra, G. J. et al. Blunted hypoxic pulmonary vasoconstriction in experimental neonatal chronic lung disease. *Am. J. Respir. Crit. Care Med.* **178**, 399–406 (2008).
52. Zhou, Y. Q. et al. Comprehensive transthoracic cardiac imaging in mice using ultrasound biomicroscopy with anatomical confirmation by magnetic resonance imaging. *Physiol. Genomics* **18**, 232–244 (2004).
53. Bossone, E., Bodini, B. D., Mazza, A. & Allegra, L. Pulmonary arterial hypertension: the key role of echocardiography. *Chest* **127**, 1836–1843 (2005).
54. Abbas, A. E. et al. A simple method for noninvasive estimation of pulmonary vascular resistance. *J. Am. Coll. Cardiol.* **41**, 1021–1027 (2003).
55. Hannemann, J., Zummack, J., Hillig, J. & Boger, R. Metabolism of asymmetric dimethylarginine in hypoxia: from bench to bedside. *Pulm. Circ.* **10**, 2045894020918846 (2020).
56. Thibault, H. B. et al. Noninvasive assessment of murine pulmonary arterial pressure: validation and application to models of pulmonary hypertension. *Circ. Cardiovasc. Imaging* **3**, 157–163 (2010).
57. Zhu, Z. et al. Echocardiographic assessment of right ventricular function in experimental pulmonary hypertension. *Pulm. Circ.* **9**, 2045894019841987 (2019).
58. Summer, R. et al. Adiponectin deficiency: a model of pulmonary hypertension associated with pulmonary vascular disease. *Am. J. Physiol. Lung Cell Mol. Physiol.* **297**, L432–L438 (2009).
59. Shah, M., Phillips, M. R., Quintana, M., Stupp, G. & McLean, S. E. Echocardiography allows for analysis of pulmonary arterial flow in mice with congenital diaphragmatic hernia. *J. Surg. Res.* **221**, 35–42 (2018).
60. Reynolds, C. L., Zhang, S., Shrestha, A. K., Barrios, R. & Shivanna, B. Phenotypic Assessment of pulmonary hypertension using high-resolution echocardiography is feasible in neonatal mice with experimental bronchopulmonary dysplasia and pulmonary hypertension: a step toward preventing chronic obstructive pulmonary disease. *Int. J. Chron. Obstruct. Pulmon. Dis.* **11**, 1597–1605 (2016).
61. Morty, R. E. Using experimental models to identify pathogenic pathways and putative disease management targets in bronchopulmonary dysplasia. *Neonatology* **117**, 233–239 (2020).
62. Wacker, C. M. et al. The pulmonary artery acceleration time determined with the mr-race-technique: comparison to pulmonary artery mean pressure in 12 patients. *Magn. Reson. Imaging* **12**, 25–31 (1994).
63. Baumgartner, H. et al. Echocardiographic assessment of valve stenosis: eae/ase recommendations for clinical practice. *J. Am. Soc. Echocardiogr.* **22**, 1–23 (2009). quiz 101–102.
64. Ehrmann, D. E. et al. Echocardiographic measurements of right ventricular mechanics in infants with bronchopulmonary dysplasia at 36 weeks post-menstrual age. *J. Pediatr.* **203**, 210–217.e211 (2018).
65. McCrary, A. W. et al. Differences in eccentricity index and systolic-diastolic ratio in extremely low-birth-weight infants with bronchopulmonary dysplasia at risk of pulmonary hypertension. *Am. J. Perinatol.* **33**, 57–62 (2016).
66. Abraham, S. & Weismann, C. G. Left ventricular end-systolic eccentricity index for assessment of pulmonary hypertension in infants. *Echocardiography* **33**, 910–915 (2016).
67. Lindsey, M. L., Kassiri, Z., Virag, J. A. I., de Castro Bras, L. E. & Scherrer-Crosbie, M. Guidelines for measuring cardiac physiology in mice. *Am. J. Physiol. Heart Circ. Physiol.* **314**, H733–H752 (2018).
68. Truong, U. et al. Update on noninvasive imaging of right ventricle dysfunction in pulmonary hypertension. *Cardiovasc. Diagn. Ther.* **10**, 1604–1624 (2020).
69. Pinar, I. P. & Jones, H. D. Novel imaging approaches for small animal models of lung disease (2017 Grover Conference Series). *Pulm. Circ.* **8**, 2045894018762242 (2018).
70. de Boode, W. P. et al. Application of neonatologist performed echocardiography in the assessment and management of persistent pulmonary hypertension of the newborn. *Pediatr. Res.* **84**, 68–77 (2018).
71. Saraswat, V. Effects of anaesthesia techniques and drugs on pulmonary function. *Indian J. Anaesth.* **59**, 557–564 (2015).
72. Trachsel, D., Svendsen, J., Erb, T. O. & von Ungern-Sternberg, B. S. Effects of anaesthesia on paediatric lung function. *Br. J. Anaesth.* **117**, 151–163 (2016).
73. Gille, J. et al. Perioperative anesthesiological management of patients with pulmonary hypertension. *Anesthesiol. Res. Pract.* **2012**, 356982 (2012).
74. Yock, P. G. & Popp, R. L. Noninvasive estimation of right ventricular systolic pressure by doppler ultrasound in patients with tricuspid regurgitation. *Circulation* **70**, 657–662 (1984).
75. Subhedar, N. V. & Shaw, N. J. Changes in pulmonary arterial pressure in preterm infants with chronic lung disease. *Arch. Dis. Child Fetal Neonatal Ed.* **82**, F243–F247 (2000).
76. Chow, L. C., Dittrich, H. C., Hoit, B. D., Moser, K. M. & Nicod, P. H. Doppler assessment of changes in right-sided cardiac hemodynamics after pulmonary thromboendarterectomy. *Am. J. Cardiol.* **61**, 1092–1097 (1988).
77. Mourani, P. M. et al. Early pulmonary vascular disease in preterm infants at risk for bronchopulmonary dysplasia. *Am. J. Respir. Crit. Care Med.* **191**, 87–95 (2015).
78. Benatar, A., Clarke, J. & Silverman, M. Pulmonary hypertension in infants with chronic lung disease: non-invasive evaluation and short term effect of oxygen treatment. *Arch. Dis. Child Fetal Neonatal Ed.* **72**, F14–F19 (1995).
79. Groh, G. K. et al. Doppler echocardiography inaccurately estimates right ventricular pressure in children with elevated right heart pressure. *J. Am. Soc. Echocardiogr.* **27**, 163–171 (2014).
80. Levy, P. T., El Khuffash, A., Woo, K. V. & Singh, G. K. Right ventricular-pulmonary vascular interactions: an emerging role for pulmonary artery acceleration time by echocardiography in adults and children. *J. Am. Soc. Echocardiogr.* **31**, 962–964 (2018).
81. Fitzgerald, D., Evans, N., Van Asperen, P. & Henderson-Smart, D. Subclinical persisting pulmonary hypertension in chronic neonatal lung disease. *Arch. Dis. Child Fetal Neonatal Ed.* **70**, F118–F122 (1994).
82. Reller, M. D., Morton, M. J., Reid, D. L. & Thornburg, K. L. Fetal lamb ventricles respond differently to filling and arterial pressures and to in utero ventilation. *Pediatr. Res.* **22**, 621–626 (1987).

AUTHOR CONTRIBUTIONS

Conception and design: J.K.T., R.A.M.; data acquisition: T.A.S., H.A., R.A.M., H.W.G.; data analysis: H.W.G., C.R.C.; drafting manuscript: J.K.T., R.A.M.; revising article: J.K.T., L.D.N.; approve of the final version to be published: J.K.T., H.A., L.D.N., T.A.S., C.R.C., H.W.G., and R.A.M.

FUNDING INFORMATION

This work was supported by NIH NHLBI K08 HL129080 (PI: J.K.T.) and the Abigail Wexner Research Institute at Nationwide Children's Hospital.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to Jennifer K. Trittman.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc 2021